Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18340154 | 0.85 | CYP2A13 (0.43) | CYP2A13KMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL3400377 | 0.84 | CYP2A13 (0.49) | CYP2A13KMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL2106701 | 0.83 | ALDH1A1 (0.46) | KMT2AALDH1A1MEN1HSD17B10HRH3 | |
| SCHEMBL13746519 | 0.82 | CYP2A13 (0.51) | CYP2A13KMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL20465105 | 0.82 | CYP2A13 (0.51) | CYP2A13KMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL1427472 | 0.81 | ALDH1A1 (0.49) | KMT2AALDH1A1MEN1HSD17B10HRH3 | |
| SCHEMBL4289837 | 0.79 | CHKA (0.55) | ALDH1A1MAPTKDM4ETSHR | |
| SCHEMBL4048591 | 0.79 | KDM4E (0.55) | CYP2A13KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL3397376 | 0.79 | GFER (0.51) | KMT2AALDH1A1MEN1CYP2C9MAPT | |
| SCHEMBL1930020 | 0.78 | CYP2A13 (0.61) | CYP2A13ALDH1A1HSD17B10CYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2836483-B1 | ANTI-MALARIAL AGENTS | MERCK PATENT GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-2836483-B1 | ANTI-MALARIAL AGENTS | MERCK PATENT GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| CN-104302624-B | Antimalarial agent | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | CN | disclosed |
| US-9115088-B2 | Anti-malarial agents | MERCK PATENT GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115088-B2 | Anti-malarial agents | MERCK PATENT GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115088-B2 | Anti-malarial agents | MERCK PATENT GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| EP-2836483-A1 | ANTI-MALARIAL AGENTS | University Of Dundee (GB) | 2015-02-18 | — | — | EP | disclosed |
| US-20150045354-A1 | Anti-Malarial Agents | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20150045354-A1 | Anti-Malarial Agents | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20150045354-A1 | Anti-Malarial Agents | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| EP-2155201-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | CYP2A13 2329/4885KMT2A 813/4885ALDH1A1 3217/4885 |
| US-20150045354-A1 | Anti-Malarial Agents | PRMT7, MRPS7, RAB7A | CYP2A13 1532/4885KMT2A 2494/4885ALDH1A1 2166/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CYP2A13 770/4885KMT2A 1885/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.